ECRI Portfolio
Severe Allergic Diseases (e.g., Asthma, Urticaria)
Pre-clinicalActive
Key Facts
Indication
Severe Allergic Diseases (e.g., Asthma, Urticaria)
Phase
Pre-clinical
Status
Active
Company
About Excellergy
Excellergy is a private, pre-revenue biotech developing first-in-class trifunctional Effector Cell Response Inhibitors (ECRIs) for severe allergic diseases. Its platform targets the fundamental limitations of existing IgE-targeting therapies by directly removing IgE from mast cells and basophils without triggering activation, potently neutralizing free IgE, and driving receptor downregulation. Backed by $70M in Series A funding from top-tier investors and led by a seasoned CEO with a strong commercial track record, the company is advancing a portfolio of programs with the potential to redefine the standard of care in allergy treatment.
View full company profile